Literature DB >> 2846199

Evidence for two components of sodium channel block by lidocaine in isolated cardiac myocytes.

C W Clarkson1, C H Follmer, R E Ten Eick, L M Hondeghem, J Z Yeh.   

Abstract

The effects of lidocaine on sodium current in cardiac myocytes isolated from cat and guinea pig were investigated using the whole-cell variation of the patch-clamp technique. Lidocaine (43-200 microM) reduced sodium current during repetitive depolarizing pulses in a use-dependent manner. To clarify the nature of the use-dependent block, we characterized the time course of block development using a two-pulse protocol. Two distinct phases of block development were found: a rapid phase (tau = 1-6 msec) having a time course concurrent with the time course of channel activation, and a slower phase (tau = 100-900 msec), which developed after channels inactivated. The amplitude of the block during the rapid phase of development was a steep function of transmembrane voltage over the range of -70 to +20 mV. The voltage-dependence was similar to that for sodium channel activation (sodium conductance) but was too steep to be attributed solely to the passive movement of a singly charged molecule under the influence of the transmembrane voltage gradient. These results suggest that use-dependent block of sodium channels in cardiac tissue may result from an interaction of lidocaine with sodium channels in the activated as well as the inactivated channel states. Possible mechanisms underlying the fast component of block are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846199     DOI: 10.1161/01.res.63.5.869

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  27 in total

1.  Blockade of cardiac sodium channels. Competition between the permeant ion and antiarrhythmic drugs.

Authors:  M J Barber; D J Wendt; C F Starmer; A O Grant
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  Rate-dependent activation failure in isolated cardiac cells and tissue due to Na+ channel block.

Authors:  Anthony Varghese; Anthony J Spindler; David Paterson; Denis Noble
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-04       Impact factor: 4.733

3.  Modification of Na channel inactivation by alpha-chymotrypsin in single cardiac myocytes.

Authors:  C W Clarkson
Journal:  Pflugers Arch       Date:  1990-09       Impact factor: 3.657

4.  Dual effect of the local anaesthetic penticainide on the Na+ current of guinea-pig ventricular myocytes.

Authors:  R Gruber; J Vereecke; E Carmeliet
Journal:  J Physiol       Date:  1991-04       Impact factor: 5.182

5.  Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre.

Authors:  E Benoit; D Escande
Journal:  Pflugers Arch       Date:  1991-12       Impact factor: 3.657

6.  Electromechanical and atrial and ventricular antiarrhythmic actions of CIJ-3-2F, a novel benzyl-furoquinoline vasodilator in rat heart.

Authors:  Gwo-Jyh Chang; Yung-Hsin Yeh; Tsung-Pin Lin; Chi-Jen Chang; Wei-Jan Chen
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

7.  Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells.

Authors:  A O Grant; R Chandra; C Keller; M Carboni; C F Starmer
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

8.  Combined effects of different class I antiarrhythmic agents on maximum rate of depolarization (Vmax) of action potentials in guinea-pig papillary muscles.

Authors:  M Hiraoka; J Nitta; A Sunami; T Sawanobori
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

9.  State-dependent trapping of flecainide in the cardiac sodium channel.

Authors:  Eugene Ramos; Michael E O'leary
Journal:  J Physiol       Date:  2004-07-22       Impact factor: 5.182

Review 10.  Emerging pharmacotherapy of tinnitus.

Authors:  Berthold Langguth; Richard Salvi; Ana Belén Elgoyhen
Journal:  Expert Opin Emerg Drugs       Date:  2009-12       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.